Cargando…

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer

The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship between CA-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Piatek, Szymon, Panek, Grzegorz, Lewandowski, Zbigniew, Piatek, Dominika, Kosinski, Przemyslaw, Bidzinski, Mariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440776/
https://www.ncbi.nlm.nih.gov/pubmed/34521891
http://dx.doi.org/10.1038/s41598-021-97564-1
_version_ 1783752735649169408
author Piatek, Szymon
Panek, Grzegorz
Lewandowski, Zbigniew
Piatek, Dominika
Kosinski, Przemyslaw
Bidzinski, Mariusz
author_facet Piatek, Szymon
Panek, Grzegorz
Lewandowski, Zbigniew
Piatek, Dominika
Kosinski, Przemyslaw
Bidzinski, Mariusz
author_sort Piatek, Szymon
collection PubMed
description The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship between CA-125 and survival was examined by applying generalized additive models to the Cox proportional hazards model. The median CA-125 concentration after the treatment was 10 U/ml (2.7–35 U/ml). The nadir CA-125 was related to progression-free survival but not to overall survival. The risk of recurrence in patients with 11–25 U/ml and 26–35 U/ml compared to patients with ≤ 10 U/ml was 1.87 (p < 0.0024) and 2.17 (p < 0.018), respectively. An increased risk of recurrence according to the nadir CA-125 (≤ 10 U/ml vs. 11–25 U/ml and ≤ 10 U/ml vs. 26–35 U/ml) was found in patients with high-grade tumours (hazard ratio, HR = 2.08 and 2.59, respectively), advanced disease (HR = 2.38 and 2.03, respectively), serous histology (HR = 2.08 and 2.43, respectively) and after complete cytoreduction (HR = 2.7 and 2.72, respectively). No correlation between the CA-125 nadir and recurrence risk was found in patients with early-stage disease or those receiving neoadjuvant chemotherapy or bevacizumab.
format Online
Article
Text
id pubmed-8440776
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84407762021-09-20 Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer Piatek, Szymon Panek, Grzegorz Lewandowski, Zbigniew Piatek, Dominika Kosinski, Przemyslaw Bidzinski, Mariusz Sci Rep Article The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship between CA-125 and survival was examined by applying generalized additive models to the Cox proportional hazards model. The median CA-125 concentration after the treatment was 10 U/ml (2.7–35 U/ml). The nadir CA-125 was related to progression-free survival but not to overall survival. The risk of recurrence in patients with 11–25 U/ml and 26–35 U/ml compared to patients with ≤ 10 U/ml was 1.87 (p < 0.0024) and 2.17 (p < 0.018), respectively. An increased risk of recurrence according to the nadir CA-125 (≤ 10 U/ml vs. 11–25 U/ml and ≤ 10 U/ml vs. 26–35 U/ml) was found in patients with high-grade tumours (hazard ratio, HR = 2.08 and 2.59, respectively), advanced disease (HR = 2.38 and 2.03, respectively), serous histology (HR = 2.08 and 2.43, respectively) and after complete cytoreduction (HR = 2.7 and 2.72, respectively). No correlation between the CA-125 nadir and recurrence risk was found in patients with early-stage disease or those receiving neoadjuvant chemotherapy or bevacizumab. Nature Publishing Group UK 2021-09-14 /pmc/articles/PMC8440776/ /pubmed/34521891 http://dx.doi.org/10.1038/s41598-021-97564-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Piatek, Szymon
Panek, Grzegorz
Lewandowski, Zbigniew
Piatek, Dominika
Kosinski, Przemyslaw
Bidzinski, Mariusz
Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_full Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_fullStr Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_full_unstemmed Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_short Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_sort nadir ca-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440776/
https://www.ncbi.nlm.nih.gov/pubmed/34521891
http://dx.doi.org/10.1038/s41598-021-97564-1
work_keys_str_mv AT piatekszymon nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer
AT panekgrzegorz nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer
AT lewandowskizbigniew nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer
AT piatekdominika nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer
AT kosinskiprzemyslaw nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer
AT bidzinskimariusz nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer